Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263772/
Yan Zhang,# 1 , # Junying Xu,# 2 , # Qiong Wang,# 3 , # Guohong Ling, 4 Yong Mao, 5 Maohuai Cai, 6 Yang Yang, 7 Jingfeng Mei, 1 Zhengxiang Han, 8 Jifeng Feng, 1 Yuan Wu, 1 Lin Shi, 1 Shaodi Wen, 1 and Bo Shen 1 For advanced gastric cancer (GC) patients who fail first-line treatment, chemotherapy alone is of limited benefit.
Conclusions: The combination of apatinib and chemotherapy demonstrated clinical activity and acceptable toxicity as a second-line treatment for advanced GC, and may provide new second-line treatment options for advanced GC patients.